These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23622932)

  • 1. Immunogenicity in biologic therapy: implications for dermatology.
    Carrascosa JM
    Actas Dermosifiliogr; 2013; 104(6):471-9. PubMed ID: 23622932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview.
    Fernandez L; Bustos RH; Zapata C; Garcia J; Jauregui E; Ashraf GM
    Curr Protein Pept Sci; 2018; 19(10):958-971. PubMed ID: 28847291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical use of biologic therapy in dermatology: some considerations and checklists.
    Ortleb M; Levitt JO
    Dermatol Online J; 2012 Feb; 18(2):2. PubMed ID: 22398223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Opinion of Spanish dermatologists regarding the use of biologic therapy in patients with moderate to severe psoriasis].
    Ara M; Pérez A; Ferrando J
    Actas Dermosifiliogr; 2011 Nov; 102(9):706-16. PubMed ID: 21600532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes.
    Jullien D; Prinz JC; Nestle FO
    J Invest Dermatol; 2015 Jan; 135(1):31-38. PubMed ID: 25120005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis].
    Jullien D
    Ann Dermatol Venereol; 2012 Apr; 139 Suppl 2():S58-67. PubMed ID: 22541730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
    Smith EC; Riddle C; Menter MA; Lebwohl M
    Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What have we learned in dermatology from the biologic therapies?
    Nickoloff BJ; Stevens SR
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S143-51. PubMed ID: 16488330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Present and future of biologic therapy in dermatology].
    Sánchez-Carazo JL
    Actas Dermosifiliogr; 2008 Mar; 99(2):89-90. PubMed ID: 18346429
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of severe psoriasis.
    Puig L
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():17-8. PubMed ID: 22758913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: the 'future' of biologic therapy?
    Ranjan N; Mahajan VK; Misra M
    J Dermatolog Treat; 2011 Dec; 22(6):319-22. PubMed ID: 20666673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
    Ortonne JP; Prinz JC
    Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?
    Sterry W; van de Kerkhof P
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():9-16. PubMed ID: 22758912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk and psoriasis: the role of biologic therapy.
    Puig L
    Actas Dermosifiliogr; 2012 Dec; 103(10):853-62. PubMed ID: 23157913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of biological therapeutics: from assay to patient.
    Krieckaert C; Rispens T; Wolbink G
    Curr Opin Rheumatol; 2012 May; 24(3):306-11. PubMed ID: 22388644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].
    Puig L; Bordas X; Carrascosa JM; Daudén E; Ferrándiz C; Hernanz JM; López-Estebaranz JL; Moreno JC; Sánchez-Carazo JL; Vanaclocha F; Vázquez-Veiga H;
    Actas Dermosifiliogr; 2009 May; 100(4):277-86. PubMed ID: 19463230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.